<p>Amgen Inc. highlighted its broad and diversified portfolio across four main therapeutic areas: general medicine, rare disease, oncology, and inflammation, at the 44th Annual J.P. Morgan Healthcare Conference. The company reported strong performance in its BiTE® platform, noting significant sales growth and clinical advances, particularly in small cell lung cancer and B-cell precursor acute lymphoblastic leukemia. Amgen also outlined progress in its pipeline, including the advancement of Xaluritamig (formerly AMG 509) into Phase 3 trials for prostate cancer. The company announced five FDA approvals, a 25% reduction in risk of major cardiovascular events with Repatha® in the VESALIUS-CV Phase 3 study, and substantial growth in biosimilar sales. Amgen emphasized six key growth drivers expected to support product sales through the end of the decade, focusing on large, underpenetrated disease areas and portfolios with multiple growth opportunities. You can access the full presentation through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amgen Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here</p>

Amgen Highlights Pipeline Advances and Growth Across Oncology, Rare Disease, Inflammation, and General Medicine in New Presentation